Leukemia research最新文献

英文中文

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2026-01-01

引用次数: 0

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2026-01-01

引用次数: 0

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2026-01-01

引用次数: 0

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2026-01-01

引用次数: 0

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2026-01-01

引用次数: 0

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2026-01-01

引用次数: 0

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2026-01-01

引用次数: 0

Outcomes of two distinct T-cell depletion strategies in haploidentical vs unrelated donor pediatric HSCT: A single-center retrospective analysis 两种不同的t细胞消耗策略在单倍体与非相关供体儿童HSCT中的结果：一项单中心回顾性分析

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2025-12-23 DOI: 10.1016/j.leukres.2025.108150

Luisa Sisinni , Odelaisy León-Triana , Mikel Fernandez Artazcoz , Mauro Guariento , Iñigo Figueroa Real de Asua , Yasmina Mozo del Castillo , Paula Lazaro del Campo , David Bueno Sanchez , Carmen Mestre Durán , Jordi Minguillón Pedreño , Mercedes Gasior Kabat , Antonio Pérez-Martínez

We conducted a single-center retrospective analysis of 49 consecutive pediatric and AYA (adolescent and young adult) patients who underwent either T-cell receptor alpha/beta and CD19-depleted unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) (TCRαβ/CD19-depleted URD HSCT; n = 22, including 13 matched unrelated donors [MUD] and 9 mismatched unrelated donors [MMUD]) or CD45RA⁺-depleted haploidentical (HAPLO) HSCT (CD45RA⁺-depleted HAPLO HSCT; n = 27) between 2018 and 2023 for malignant hematological disorders. Both groups showed comparable engraftment kinetics. Primary graft failure occurred in four patients (8.5 %), predominantly in the HAPLO group. Acute graft-versus-host disease (aGvHD) grade II–IV occurred in 72.9 % of patients, with the highest incidence in the MMUD subgroup (89 %; p = 0.03). Chronic GvHD (cGvHD) was observed in 42.6 % of patients, with a tendency toward a higher incidence in the MMUD group (67 % vs 38 % for MUD and 33 % for HAPLO; p = 0.08). The 2-year overall survival (OS) was 75.5 %, with no significant differences between groups (MUD 92.3 %, MMUD 77.7 %, HAPLO 66.6 %; p = 0.34). GvHD-free/relapse-free survival (GRFS) at 2 years favored MUD (51.9 %) and HAPLO (51.3 %) over MMUD (22.2 %), with significantly poorer GRFS in MMUD compared with HAPLO (p = 0.038). In multivariate analysis, disease status ≥ third complete remission (≥CR3) at HSCT was associated with significantly poorer OS (hazard ratio [HR] 13, 95 % confidence interval [CI] 1.2–130; p = 0.036), while sex mismatch (female donor to male recipient) was associated with inferior GRFS (HR 4.5, 95 % CI 1.6–12; p = 0.0035). Our results highlight the feasibility of both HAPLO and URD HSCT in children with malignancies, using distinct T-cell depletion strategies tailored to donor type. However, our findings also indicate that ex vivo T-cell depletion alone, without additional GvHD prophylaxis, is insufficient to prevent GvHD, underscoring the need for combined strategies to improve outcomes.

我们对49名连续接受t细胞受体α / β和cd19缺失非相关供体（URD）造血干细胞移植（HSCT）（TCRαβ/ cd19缺失URD HSCT； n = 22，包括13名匹配的非相关供体[MUD]和9名错配的非相关供体[MMUD]）或CD45RA + -缺失HAPLO HSCT (CD45RA + -缺失HAPLO HSCT；N = 27)在2018年至2023年恶性血液病。两组的移植物动力学相当。4例患者发生原发性移植物衰竭（8.5 %），主要发生在HAPLO组。急性移植物抗宿主病（aGvHD） II-IV级发生率为72.9 %，其中MMUD亚组发生率最高（89 %;p = 0.03）。慢性GvHD （cGvHD）在42.6 %的患者中观察到，MMUD组的发病率有更高的趋势（67 % vs 38 % MUD和33 % HAPLO； p = 0.08）。2年总生存率（OS）为75.5 %，组间差异无统计学意义（MUD 92.3 %,MMUD 77.7 %,HAPLO 66.6 %;p = 0.34）。2年无gvhd /无复发生存率（GRFS）在MUD（51.9 %）和HAPLO（51.3 %）优于MMUD(22.2% %)，MMUD的GRFS明显低于HAPLO （p = 0.038）。在多变量分析中，HSCT的疾病状态≥ 第三次完全缓解（≥CR3）与较差的OS相关（风险比[HR] 13,95 %置信区间[CI] 1.2-130; p = 0.036），而性别不匹配（女性供体与男性受体）与较差的GRFS相关（HR 4.5, 95 % CI 1.6-12; p = 0.0035）。我们的研究结果强调了HAPLO和URD HSCT在儿童恶性肿瘤中的可行性，使用针对供体类型量身定制的不同t细胞消耗策略。然而，我们的研究结果也表明，单独的体外t细胞消耗，没有额外的GvHD预防，不足以预防GvHD，强调需要联合策略来改善结果。

{"title":"Outcomes of two distinct T-cell depletion strategies in haploidentical vs unrelated donor pediatric HSCT: A single-center retrospective analysis","authors":"Luisa Sisinni , Odelaisy León-Triana , Mikel Fernandez Artazcoz , Mauro Guariento , Iñigo Figueroa Real de Asua , Yasmina Mozo del Castillo , Paula Lazaro del Campo , David Bueno Sanchez , Carmen Mestre Durán , Jordi Minguillón Pedreño , Mercedes Gasior Kabat , Antonio Pérez-Martínez","doi":"10.1016/j.leukres.2025.108150","DOIUrl":"10.1016/j.leukres.2025.108150","url":null,"abstract":"<div><div>We conducted a single-center retrospective analysis of 49 consecutive pediatric and AYA (adolescent and young adult) patients who underwent either T-cell receptor alpha/beta and CD19-depleted unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) (TCRαβ/CD19-depleted URD HSCT; n = 22, including 13 matched unrelated donors [MUD] and 9 mismatched unrelated donors [MMUD]) or CD45RA⁺-depleted haploidentical (HAPLO) HSCT (CD45RA⁺-depleted HAPLO HSCT; n = 27) between 2018 and 2023 for malignant hematological disorders. Both groups showed comparable engraftment kinetics. Primary graft failure occurred in four patients (8.5 %), predominantly in the HAPLO group. Acute graft-versus-host disease (aGvHD) grade II–IV occurred in 72.9 % of patients, with the highest incidence in the MMUD subgroup (89 %; p = 0.03). Chronic GvHD (cGvHD) was observed in 42.6 % of patients, with a tendency toward a higher incidence in the MMUD group (67 % vs 38 % for MUD and 33 % for HAPLO; p = 0.08). The 2-year overall survival (OS) was 75.5 %, with no significant differences between groups (MUD 92.3 %, MMUD 77.7 %, HAPLO 66.6 %; p = 0.34). GvHD-free/relapse-free survival (GRFS) at 2 years favored MUD (51.9 %) and HAPLO (51.3 %) over MMUD (22.2 %), with significantly poorer GRFS in MMUD compared with HAPLO (p = 0.038). In multivariate analysis, disease status ≥ third complete remission (≥CR3) at HSCT was associated with significantly poorer OS (hazard ratio [HR] 13, 95 % confidence interval [CI] 1.2–130; p = 0.036), while sex mismatch (female donor to male recipient) was associated with inferior GRFS (HR 4.5, 95 % CI 1.6–12; p = 0.0035). Our results highlight the feasibility of both HAPLO and URD HSCT in children with malignancies, using distinct T-cell depletion strategies tailored to donor type. However, our findings also indicate that ex vivo T-cell depletion alone, without additional GvHD prophylaxis, is insufficient to prevent GvHD, underscoring the need for combined strategies to improve outcomes.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108150"},"PeriodicalIF":2.2,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145834238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories 急性髓性白血病融合基因和PCR检测的突变靶点的实验室间交叉验证：PETHEMA中心实验室的表现。

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2025-12-19 DOI: 10.1016/j.leukres.2025.108149

Margarida Coucelo , Claudia Sargas , Rosa Ayala , María J. Larráyoz , María Carmen Chillón , Elena Soria , Cristina Bilbao , Esther Prados de la Torre , Maria Luis Amorim , Alberto Mirales , Antonia Cionfrini , Ana T. Simões , Ana C. Oliveira , Rebeca Rodríguez-Veiga , Pilar Lloret-Madrid , Yolanda Mendizábal , Carmen Botella , Teresa Bernal , Juan Bergua , Lorenzo Algarra , Eva Barragán

The rapid and accurate laboratory identification of targetable therapeutic genes, together with the implementation of measurable residual disease (MRD) based decision is essential for optimal clinical management in acute myeloid leukemia (AML). The PETHEMA (Programa Español de Tratamientos en Hematología) cooperative group comprises nine laboratories that perform centralized molecular studies by conventional PCR and Real-time quantitative PCR (RT-qPCR) for AML patients. With the aim to validate laboratories performances, we conducted three rounds of interlaboratory cross validation (ICV) for the quantification of CBFB::MYH11, RUNX1::RUNX1T1 and NPM1 and one round to determine the mutational status of NPM1, FLT3 (ITD and TKD2) IDH1 and IDH2. For RT-qPCR a total of 19 samples were tested and only 3 (15.8 %) failed to achieve 100 % concordance, corresponding to samples with low target gene mean ratios (ICV1-S4, ICV2-S1, ICV2-S6). For mutation detection in a total of 227 returned results, concordance rate ranged from 95 % to 100 %. FLT3-ITD and NPM1 mutation detection had 100 % concordant results. One false negative was reported for IDH2- R140 mutation and 4 false positives were detected: 2 FLT3-TKD2 and 2 IDH1-R132, likely reflecting differences in assay sensitivity. Overall, the results were highly satisfactory, particularly regarding MRD assessment, and highlighted key points for improvement, especially in baseline detection of FLT3-TKD2 and IDH1 mutations. This study represents the first collaborative initiative to evaluate performance of AML molecular targets within a laboratory network and underscores the importance of regular exercises to monitor performance, identify and resolve technical or interpretive discrepancies to ultimately ensure accurate clinical decision-making.

快速准确的实验室鉴定靶向治疗基因，以及基于可测量残留病（MRD）的决策的实施，对于急性髓性白血病（AML）的最佳临床管理至关重要。PETHEMA （Programa Español de Tratamientos en Hematología）合作小组由9个实验室组成，通过传统PCR和实时定量PCR （RT-qPCR）对AML患者进行集中的分子研究。为了验证实验室性能，我们进行了三轮实验室间交叉验证（ICV）来量化CBFB::MYH11、RUNX1::RUNX1T1和NPM1，并进行了一轮实验室间交叉验证（ICV）来确定NPM1、FLT3 (ITD和TKD2) IDH1和IDH2的突变状态。RT-qPCR共检测了19个样本，只有3个（15.8 %）未能达到100 %的一致性，对应于低靶基因平均比率的样本（ICV1-S4, ICV2-S1, ICV2-S6）。对于227个返回结果的突变检测，一致性率从95 %到100 %不等。FLT3-ITD与NPM1突变检测结果吻合度为100% %。报告了1例IDH2- R140突变假阴性和4例假阳性：2例FLT3-TKD2和2例IDH1-R132，可能反映了测定敏感性的差异。总体而言，结果非常令人满意，特别是在MRD评估方面，并强调了改进的关键点，特别是在FLT3-TKD2和IDH1突变的基线检测方面。该研究是首次在实验室网络中评估AML分子靶点表现的合作倡议，并强调了定期锻炼以监测表现、识别和解决技术或解释差异的重要性，最终确保准确的临床决策。

{"title":"Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories","authors":"Margarida Coucelo , Claudia Sargas , Rosa Ayala , María J. Larráyoz , María Carmen Chillón , Elena Soria , Cristina Bilbao , Esther Prados de la Torre , Maria Luis Amorim , Alberto Mirales , Antonia Cionfrini , Ana T. Simões , Ana C. Oliveira , Rebeca Rodríguez-Veiga , Pilar Lloret-Madrid , Yolanda Mendizábal , Carmen Botella , Teresa Bernal , Juan Bergua , Lorenzo Algarra , Eva Barragán","doi":"10.1016/j.leukres.2025.108149","DOIUrl":"10.1016/j.leukres.2025.108149","url":null,"abstract":"<div><div>The rapid and accurate laboratory identification of targetable therapeutic genes, together with the implementation of measurable residual disease (MRD) based decision is essential for optimal clinical management in acute myeloid leukemia (AML). The PETHEMA (Programa Español de Tratamientos en Hematología) cooperative group comprises nine laboratories that perform centralized molecular studies by conventional PCR and Real-time quantitative PCR (RT-qPCR) for AML patients. With the aim to validate laboratories performances, we conducted three rounds of interlaboratory cross validation (ICV) for the quantification of <em>CBFB::MYH11, RUNX1::RUNX1T1</em> and <em>NPM1</em> and one round to determine the mutational status of <em>NPM1</em>, <em>FLT3</em> (ITD and TKD2) <em>IDH1</em> and <em>IDH2</em>. For RT-qPCR a total of 19 samples were tested and only 3 (15.8 %) failed to achieve 100 % concordance, corresponding to samples with low target gene mean ratios (ICV1-S4, ICV2-S1, ICV2-S6). For mutation detection in a total of 227 returned results, concordance rate ranged from 95 % to 100 %. <em>FLT3</em>-ITD and <em>NPM1</em> mutation detection had 100 % concordant results. One false negative was reported for <em>IDH2</em>- R140 mutation and 4 false positives were detected: 2 <em>FLT3</em>-TKD2 and 2 <em>IDH1</em>-R132, likely reflecting differences in assay sensitivity. Overall, the results were highly satisfactory, particularly regarding MRD assessment, and highlighted key points for improvement, especially in baseline detection of <em>FLT3</em>-TKD2 and <em>IDH1</em> mutations. This study represents the first collaborative initiative to evaluate performance of AML molecular targets within a laboratory network and underscores the importance of regular exercises to monitor performance, identify and resolve technical or interpretive discrepancies to ultimately ensure accurate clinical decision-making.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108149"},"PeriodicalIF":2.2,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Double IGHV rearrangements in a Latin American cohort of chronic lymphocytic leukemia patients 拉丁美洲慢性淋巴细胞白血病患者的双IGHV重排。

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2025-12-19 DOI: 10.1016/j.leukres.2025.108151

Carmen Stanganelli, Juana Cabrera, Andrea Bender, Evangelina Agriello, Davi Coe Torres, Gerson Moura Ferreira, Maria Paula Mota dos Santos, Eliana Saul Furquim Werneck Abdelhay, Irma Slavutsky

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Leukemia research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀